Subscribe
shutterstock_1349458001_pavel_kapysh
Pavel Kapysh / Shutterstock.com
8 January 2020AmericasSarah Morgan

Allergan agrees to pay $300m to end birth control litigation

Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Apollo’s Covis sues over preterm-birth drug patents
5 January 2021   Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
Americas
Supermarket chain settles pay-for-delay suit over birth control pill
19 December 2019   Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.
Americas
Allergan pays $750m to resolve antitrust litigation
29 October 2019   Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Apollo’s Covis sues over preterm-birth drug patents
5 January 2021   Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
Americas
Supermarket chain settles pay-for-delay suit over birth control pill
19 December 2019   Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.
Americas
Allergan pays $750m to resolve antitrust litigation
29 October 2019   Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

More on this story

Americas
Apollo’s Covis sues over preterm-birth drug patents
5 January 2021   Aurobindo’s subsidiary Eugia allegedly infringed two patents for an injectable treatment for reducing the risk of premature birth, according to a lawsuit by Covis Pharma, a Luxembourg-based unit of Apollo Global Management.
Americas
Supermarket chain settles pay-for-delay suit over birth control pill
19 December 2019   Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.
Americas
Allergan pays $750m to resolve antitrust litigation
29 October 2019   Allergan has reached a $750 million deal to resolve antitrust litigation brought against its subsidiary Forest Laboratories over Alzheimer’s drug Namenda.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?